FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:572-580 February 26, 1998 Number 9 Next

	Full Text PDF Editorial by Schwartz, R. S. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown. Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease.

Methods Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects. The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting. Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed.

Results Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor Mpl was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of Mpl or the lack of its expression. In patients with polycythemia vera, reduced expression of Mpl by platelets was associated with reduced expression of Mpl by megakaryocytes.

Conclusions Reduced expression of the thrombopoietin receptor Mpl is characteristic of polycythemia vera and idiopathic myelofibrosis. The abnormality appears to distinguish polycythemia vera from other forms of erythrocytosis.

Source Information

From the Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Traylor 924, 720 Rutland Ave., Baltimore, MD 21205, where reprint requests should be addressed to Dr. Spivak.

Full Text of this Article

Related Letters:

Signal Transduction in Platelets from Patients with Polycythemia Vera
Lange W., Martens U. M., Waller C. F., Moliterno A. R., Hankins W. D., Spivak J. L.
Extract | Full Text  
N Engl J Med 1998; 339:127-128, Jul 9, 1998. Correspondence

This article has been cited by other articles:

• Constantinescu, S. N. (2009). Mpl and thrombocytosis: levels matter. Blood 113: 1617-1618 [Full Text]  
• Tiedt, R., Coers, J., Ziegler, S., Wiestner, A., Hao-Shen, H., Bornmann, C., Schenkel, J., Karakhanova, S., de Sauvage, F. J., Jackson, C. W., Skoda, R. C. (2009). Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 113: 1768-1777 [Abstract] [Full Text]  
• Levine, R. L., Gilliland, D. G. (2008). Myeloproliferative disorders. Blood 112: 2190-2198 [Abstract] [Full Text]  
• Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., Skoda, R. C. (2008). Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940 [Abstract] [Full Text]  
• Teofili, L., Martini, M., Cenci, T., Petrucci, G., Torti, L., Storti, S., Guidi, F., Leone, G., Larocca, L. M. (2007). Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 110: 354-359 [Abstract] [Full Text]  
• Tefferi, A. (2007). Primary myelofibrosis and its paraneoplastic stromal effects. haematol 92: 577-579 [Full Text]  
• Campbell, P. J., Green, A. R. (2006). The Myeloproliferative Disorders. NEJM 355: 2452-2466 [Full Text]  
• Moliterno, A. R., Williams, D. M., Rogers, O., Spivak, J. L. (2006). Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108: 3913-3915 [Abstract] [Full Text]  
• Bellanne-Chantelot, C., Chaumarel, I., Labopin, M., Bellanger, F., Barbu, V., De Toma, C., Delhommeau, F., Casadevall, N., Vainchenker, W., Thomas, G., Najman, A. (2006). Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108: 346-352 [Abstract] [Full Text]  
• Schafer, A. I. (2006). Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107: 4214-4222 [Abstract] [Full Text]  
• Levine, R. L., Wernig, G. (2006). Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders. ASH Education Book 2006: 233-239 [Abstract] [Full Text]  
• Staerk, J., Kallin, A., Demoulin, J.-B., Vainchenker, W., Constantinescu, S. N. (2005). JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: CROSS-TALK WITH IGF1 RECEPTOR. J. Biol. Chem. 280: 41893-41899 [Abstract] [Full Text]  
• Tefferi, A. (2005). Pathogenesis of Myelofibrosis With Myeloid Metaplasia. JCO 23: 8520-8530 [Abstract] [Full Text]  
• Goerttler, P. S., Steimle, C., Marz, E., Johansson, P. L., Andreasson, B., Griesshammer, M., Gisslinger, H., Heimpel, H., Pahl, H. L. (2005). The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 106: 2862-2864 [Abstract] [Full Text]  
• Royer, Y., Staerk, J., Costuleanu, M., Courtoy, P. J., Constantinescu, S. N. (2005). Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability. J. Biol. Chem. 280: 27251-27261 [Abstract] [Full Text]  
• Tefferi, A., Gilliland, D. G. (2005). The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis. Mayo Clin Proc. 80: 947-958 [Abstract]  
• Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., Skoda, R. C. (2005). A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. NEJM 352: 1779-1790 [Abstract] [Full Text]  
• Moliterno, A. R., Williams, D. M., Gutierrez-Alamillo, L. I., Salvatori, R., Ingersoll, R. G., Spivak, J. L. (2004). Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis. Proc. Natl. Acad. Sci. USA 101: 11444-11447 [Abstract] [Full Text]  
• Schafer, A. I. (2004). Thrombocytosis. NEJM 350: 1211-1219 [Full Text]  
• O'Brien, S., Tefferi, A., Valent, P. (2004). Chronic Myelogenous Leukemia and Myeloproliferative Disease. ASH Education Book 2004: 146-162 [Abstract] [Full Text]  
• Xu, M.-j., Sui, X., Zhao, R., Dai, C., Krantz, S. B., Zhao, Z. J. (2003). PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood 102: 4354-4360 [Abstract] [Full Text]  
• Klippel, S., Strunck, E., Temerinac, S., Bench, A. J., Meinhardt, G., Mohr, U., Leichtle, R., Green, A. R., Griesshammer, M., Heimpel, H., Pahl, H. L. (2003). Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102: 3569-3574 [Abstract] [Full Text]  
• Kralovics, R., Stockton, D. W., Prchal, J. T. (2003). Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102: 3793-3796 [Abstract] [Full Text]  
• Kralovics, R., Buser, A. S., Teo, S.-S., Coers, J., Tichelli, A., van der Maas, A. P. C., Skoda, R. C. (2003). Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102: 1869-1871 [Abstract] [Full Text]  
• Tefferi, A. (2003). Polycythemia Vera: A Comprehensive Review and Clinical Recommendations. Mayo Clin Proc. 78: 174-194 [Abstract]  
• Spivak, J. L. (2002). Polycythemia vera: myths, mechanisms, and management. Blood 100: 4272-4290 [Full Text]  
• Teofili, L., Pierconti, F., Di Febo, A., Maggiano, N., Vianelli, N., Ascani, S., Rossi, E., Pileri, S., Leone, G., Larocca, L. M., De Stefano, V. (2002). The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 100: 714-717 [Abstract] [Full Text]  
• Mesa, R. A., Hanson, C. A., Li, C.-Y., Yoon, S.-Y., Rajkumar, S. V., Schroeder, G., Tefferi, A. (2002). Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 99: 4131-4137 [Abstract] [Full Text]  
• Ballmaier, M., Germeshausen, M., Schulze, H., Cherkaoui, K., Lang, S., Gaudig, A., Krukemeier, S., Eilers, M., Strau{beta}, G., Welte, K. (2001). c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97: 139-146 [Abstract] [Full Text]  
• Tefferi, A., Elliott, M. A., Kao, P. C., Yoon, S., El-Hemaidi, I., Pearson, T. C. (2000). Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood 96: 1582-1584 [Abstract] [Full Text]  
• Tefferi, A., Yoon, S.-Y., Li, C.-Y. (2000). Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 96: 771-772 [Abstract] [Full Text]  
• Klippel, S., Strunck, E., Roder, S., Lubbert, M., Lange, W., Azemar, M., Meinhardt, G., Schaefer, H.-E., Pahl, H. L. (2000). Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95: 2569-2576 [Abstract] [Full Text]  
• Otto;, K. G., Moliterno, A. R., Spivak, J. L. (2000). Are MpI glycosylation defects in polycythemia vera secondary to artifactual hypoglycemia?. Blood 95: 2452-2453 [Full Text]  
• Letestu, R., Vitrat, N., Masse, A., Couedic, J.-P. L., Lazar, V., Rameau, P., Wendling, F., Vuillier, J., Boutard, P., Plouvier, E., Plasse, M., Favier, R., Vainchenker, W., Debili, N. (2000). Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 95: 1633-1641 [Abstract] [Full Text]  
• Pearson, T. C., Messinezy, M., Westwood, N., Green, A. R., Bench, A. J., Green, A. R., Huntly, B. J.P., Nacheva, E. P., Barbui, T., Finazzi, G. (2000). A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment. ASH Education Book 2000: 51-68 [Abstract] [Full Text]  
• Moliterno, A. R., Spivak, J. L. (1999). Posttranslational Processing of the Thrombopoietin Receptor Is Impaired in Polycythemia Vera. Blood 94: 2555-2561 [Abstract] [Full Text]  
• Barosi, G. (1999). Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines. JCO 17: 2954-2954 [Abstract] [Full Text]  
• Taksin, A. L., Couedic, J.-P. L., Dusanter-Fourt, I., Masse, A., Giraudier, S., Katz, A., Wendling, F., Vainchenker, W., Casadevall, N., Debili, N. (1999). Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L. Blood 93: 125-139 [Abstract] [Full Text]  
• Lange, W., Martens, U. M., Waller, C. F., Moliterno, A. R., Hankins, W. D., Spivak, J. L. (1998). Signal Transduction in Platelets from Patients with Polycythemia Vera. NEJM 339: 127-128 [Full Text]  
• Schwartz, R. S. (1998). Polycythemia Vera -- Chance, Death, and Mutability. NEJM 338: 613-615 [Full Text]